PIK3CA and breast carcinoma: In primary ER+ breast cancer, PIK3CA mutations correlate with better outcomes [32], whereas in the metastatic setting they predict poor prognosis [33]; accordingly, the PI3Kα-selective inhibitor alpelisib is FDA-approved for advanced ER+ breast cancer [34].